TEVA PHARMACEUTICAL INDUSTRIES LTD
Extracted from this filing and checked against the source text.
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Ratification of appointment of Kesselman & Kesselman (PricewaterhouseCoopers) as independent registered public accounting firm at the 2026-05-28 meeting.
The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2027 annual meeting of shareholders, as follows: For Against Abstain Broker non-votes 880,542,242 36,085,507 525,382 0View on SEC.gov
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Election of Director to serve until Teva's 2029 annual meeting at the 2026-05-28 meeting.
The shareholders elected to appoint the following person to the Board, to serve until Teva’s 2029 annual meeting of shareholders, as follows: For Against Abstain Broker non-votes Dr. Sol J. Barer 627,816,662 245,921,571 530,682 50,661,570View on SEC.gov
TEVA PHARMACEUTICAL INDUSTRIES LTD shareholders approved Advisory (non-binding) vote on compensation for named executive officers at the 2026-05-28 meeting.
The shareholders approved, on a non-binding advisory basis, the compensation for Teva’s named executive officers listed in the proxy statement for the Annual Meeting, as follows: For Against Abstain Broker non-votes 795,976,042 77,082,847 1,170,026 50,661,570View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.